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Purpose: The aim of this study was to compare survival in patients that underwent palliative resection treatment versus non-
resection for incurable colorectal cancer (ICRC). 
Methods: The case records of 201 patients with ICRC between January 2000 and December 2009 were reviewed. Demo-
graphics, American Society of Anesthesiologists (ASA) score, carcinoembryonic antigen (CEA) level, the location of the 
colon cancer, histology, metastasis, treatment options and median survival were analyzed retrospectively. We divided the 
patients into four groups according to the treatment modalities: resection alone, resection with post-operative chemother-
apy, non-resection treatment by chemotherapy alone, and stent or bypass. Median survival times were compared accord-
ing to each treatment option, and the survival rates were analyzed.
Results: 105 patients underwent palliative resection whereas 96 were treated with non-resection modalities. A palliative 
resection was performed in 44 cases for resection alone and in 61 cases for resection with post-operative chemotherapy. In 
patients treated with non-resection of the primary tumor, chemotherapy alone was done in 65 cases and stent or bypass in 
31 cases. Multivariate analysis showed a median survival of 14 months in patients with palliative resections with post-op-
erative chemotherapy, which was significantly higher than those for chemotherapy alone (8 months), primary tumor re-
section alone (5 months), and stent or bypass (5 months). Gender, age, ASA score, CEA level, the location of colon cancer, 
histology and the presence of multiple metastases were not independent factors in association with the median survival 
rate.
Conclusion: In the treatment of ICRC, palliative resection followed by post-operative chemotherapy shows the most fa-
vorable median survival compared to other treatment options.
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be the most effective treatment for colorectal cancer [2]. However, 
in about 20% of the cases, the colorectal cancer is found to be pro-
gressive, and complete removal of the lesion at the time of diag-
nosis is impossible; accordingly, various palliative treatments are 
required [3, 4]. Since the majority of these patients are old and 
have bad condition overall with various underlying diseases, it is 
still debatable whether surgical removal of the primary lesion will 
enhance survival rate or not [3, 5-10]. 
As non-operative methods, chemotherapy, stent insertion, and 
bypass are used. A number of studies have reported that in the 
case of chemotherapy, the median survival period and the overall 
survival rate can be increased by using a single treatment modal-
ity without removing the primary lesion [11-13]. In addition, stent 
insertion and bypass, which is expected to develop fewer compli-
cations, are restrictively chosen to relieve the symptoms of the pri-
mary obstructive lesion [3]. Further, efforts have been made to find 
the best treatment modality for advanced colorectal cancer and to 
INTRODUCTION
According to recent cancer statistics released by the Korean gov-
ernment, the incidence rate of colorectal cancer takes 3rd place, 
following stomach and thyroid cancer, and in terms of death rate, 
colorectal cancer takes 4th place, following lung cancer, liver can-
cer and stomach cancer [1]. A radical resection is understood to 
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confirm whether a palliative resection contributes to enhancing 
the survival rate of colorectal cancer patients. For these reasons, 
the authors wanted to find the optimal treatment modality by com-
paring survival rates attained by using various treatment modali-
ties for colorectal cancer.
METHODS
A group of colorectal cancer patients who were pathohistologi-
cally given a definite diagnosis of colorectal cancer and who had 
received treatments but had been confirmed as being unable to 
undergo a radical resection due to multiple or single metastasis 
findings at Chonbuk National University Hospital between Janu-
ary 2000 and December 2009 were selected. Advanced colorectal 
cancer is defined as cases with multiple lesions of the liver or with 
lung metastasis, which could not be resected according to preop-
erative findings, such as chest X-ray, chest computed tomography, 
magnetic resonance imaging, and positron emission tomography, 
or according to operative findings; cases with multiple metastasis 
findings; and cases with local invasions that could not be R0 resected 
due to disseminated peritoneal metastases, synchronous multiple 
metastasis to organs in the abdominal cavity, and lymphatic me-
tastases whose lesion could not be resected. The present study was 
carried out over 10 years and involved 207 individuals diagnosed 
with advanced colorectal cancer. Of the 207 patients, 201 individ-
uals were finally selected. Three cases that could not be monitored 
and another three cases of neuroendocrinal tumors were excluded 
from this retrospective study.
Subjects were divided by sex, age and level of anesthetic risk pro-
vided by American Society of Anesthesiologists (ASA), and cor-
relations between survival rate and location of primary lesion, pre-
treatment carcinoembryonic antigen (CEA), tumor differentiation, 
symptoms and metastasis were examined. In order to find survival 
rates by treatment modality, subjects were divided into groups of 
palliative resection, palliative resection followed by chemotherapy, 
stent insertion and bypass for comparison. Post-operative compli-
cations were defined as respiratory or wound infection, anastomotic 
leakage, bleeding, intraperitoneal abscess, ileus, voiding difficulty, 
anastomosis site obstruction, and conditions requiring additional 
surgical or medical treatments. Post-operative death was defined 
as surgery-related death occurring within 30 days of surgery.
The SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA) was used for 
statistical treatment. For the survival rate analysis, the Kaplan-Meier 
method was used. After the log rank test, statistical significance 
was established with a P-value less than 0.05. When sufficiently 
meaningful data were obtained through a univariate analysis, a 
multivariate analysis was conducted using the Cox proportional 
hazards regression model. 
RESULTS
Properties of the resection and the non-resection groups 
Out of the total 201 patients, 105 individuals (52%) underwent a 
palliative resection, and 96 (48%) were in the non-resection group 
(Fig. 1). The male-to-female ratios in the palliative resection and 
the non-resection groups were 2.18:1 (72:33) and 1.82:1 (62:34), 
respectively. The numbers of patients 75 years or older were 14 
(13.3%) and 21 (21.9%) in the respective palliative resection and 
the non-resection groups. The numbers of patients having 5 ng/mL 
or more of CEA (normal range, 0.0 to 5.0 ng/mL) prior to treat-
ment were 72 (73.5%) and 78 (83.0%) in the respective groups. 
The numbers of patients having primary lesions of colon cancer 
were 60 (57.1%) and 54 (56.2%) in the respective palliative resec-
tion and non-resection groups. In addition, the numbers of patients 
Incomplete data (n = 3)
Neuroendocrine (n = 3)
Only resection 
(n = 42)
Only chemotherapy 
(n = 62)
Resection with 
chemotherapy 
(n = 63)
Stent or bypass 
(n = 34)
Resection group 
(n = 105)
Non-resection group 
(n = 96)
Incurable CRC 
(n = 207)
Study patients 
(n = 201)
Fig. 1. Evaluation of 207 patients 
with newly diagnosed stage IV 
incurable colorectal cancer (CRC) 
at Chonbuk National University 
Hospital. Six patients were ex-
cluded due to incomplete data (3 
patients) and neuroendocrine tu-
mors (3 patients). The resection 
group included 105 patients (only 
resection, 42 patients; resection 
and chemotherapy, 63 patients). 
The non-resection group included 
96 patients (only chemotherapy, 
62 patients; stent or bypass sur-
gery, 34 patients). Journal of The Korean Society of
Coloproctology
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who had good ASA values (1 to 2) were 96 (91.4%) in the resec-
tion group and 77 (80.2%) in the non-resection group, meaning a 
better ASA score in the resection group (P = 0.02) (Table 1). 
Major complaints of the resection group at the first visit included 
abdominal pain (46.4%), bowel habit change (21.4%), and bleed-
ing (5.1%); those of the non-resection group included abdominal 
pain (31.2%), nonspecific symptoms (29.3%), and bowel habit 
change (16.4%). Ileus was confirmed with radiological findings 
with symptoms of abdominal distention and nausea. Surgery was 
conducted when the primary lesion could be surgically resected 
according to the characteristics of the tumor and the judgment of 
the surgeon (Table 2).
Properties of primary cancer
The numbers of primary cancer cases by location of the lesion in 
the respective resection and non-resection groups were 37 (35.2%) 
and 43 (44.8%) in rectum, followed by 28 (26.7%) right colon cases 
in the resection group, and 15 (15.6%) sigmoid colon cases in the 
non-resection group (Table 3). According to the results of endo-
scopic biopsies for the non-resection group and tumor differenti-
ation of the surgically-removed lesion, the number of well-differ-
entiated adenocarcinoma cases was 16 (84.2%) in the non-resec-
tion group compared with only 3 cases (15.8%) in the resection 
group (Table 4).
Metastasized lesion 
The number of hepatic metastasis cases were 50 (47.6%) and 32 
(33.3%) in the respective resection and non-resection groups, fol-
lowed by 28 (26.7%) and 24 (25.0%) of peritoneal metastasis in the 
Table 1. Baseline characteristics of study patients
Characteristic
All  
(n = 201)
Resection  
(n = 105)
Non- 
resection  
(n = 96)
P-value
Male sex 134 (66.7) 72 (68.6) 62 (64.6) 0.55
Old age (≥75 yr)   35 (17.4) 14 (13.3) 21 (21.9) 0.11
Good ASA score (1-2) 173 (86.1) 96 (91.4) 77 (80.2) 0.02
CEA elevation 
   (n = 192)
150/192 
(78.1)
72/98  
(73.5)
78/94  
(83.0)
0.11
Primary colon cancer 114 (56.7) 60 (57.1) 54 (56.2) 0.90
Multiple metastases
a   89 (44.3) 50 (47.6) 39 (40.6) 0.32
Values are presented as number (%).
ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen.
aAccording to classification of American Joint Committee on Cancer, 7th edition.
Table 2. Main presenting symptoms of patients with incurable colorec-
tal cancer
Symptom
Resection 
group
Non-resection group
Total  Chemo- 
 therapy
  Stent or  
  bypass
Pain 52 (46.4)    20 (29.4)    15 (31.2)    35 (30.2)
Obstruction 12 (10.7)    2 (2.9)      8 (16.6)  10 (8.6)
Bleeding 17 (15.1)    3 (4.4)      5 (10.4)  11 (9.5)
Bowel habit change 24 (21.4)    10 (14.7)      9 (18.7)    19 (16.4)
Screening 4 (3.6)    33 (48.5)    1 (2.0)    34 (29.3)
Palpable mass 3 (2.7) 0 (0) 0 (0) 0 (0)
Total 112
a 68 48 116
b
Values are presented as number (%).
aThere were 112 symptoms in 105 patients of the resection group; 
bThere were 
116 symptoms in 96 patients of the non-resection group.
Table 3. Sites of the primary tumor
Site
Resection  
(n = 105)
Non-resection 
(n = 96)
  Total  
  (n = 201)
Right colon 28 (26.7) 14 (14.6)   42 (20.9)
Transverse colon 8 (7.6) 9 (9.4) 17 (8.5)
Descending colon 4 (3.8) 8 (8.3) 12 (6.0)
Sigmoid colon 19 (18.1) 15 (15.6)   34 (16.9)
Recto-sigmoid colon 9 (8.6) 7 (7.3) 16 (8.0)
Rectal 37 (35.2) 43 (44.8)   80 (38.9)
Values are presented as number (%).
Table 4. Comparison of the frequency of treatment methods accord-
ing to tumor differentiation (test for trend)
Tumor differentiation
Resection
a 
(n = 105)
Non-resection
b 
(n = 96)
P-value
Well (n = 19)   3 (15.8) 16 (84.2) 0.01
Moderate (n = 140) 80 (57.1) 60 (42.9)
Poor (n = 29) 10 (34.5) 19 (65.5)
Mucinous (n = 13) 12 (92.3) 1 (7.7)
Values are presented as number (%).
aResected specimen biopsy; 
bEndoscopic biopsy.
Table 5. Sites of metastasis in incurable colorectal cancer
Site
Resection  
(n = 105)
Non-resection  
(n = 96)
P-value
a
Liver   50 (47.6) 32 (33.3) 0.174
Lung 10 (9.5) 8 (8.3) 0.681
Liver and lung   6 (5.7) 7 (7.3) 0.042
Peritoneal seeding   28 (26.7) 24 (25.0) 0.853
Pelvic organ   4 (3.8) 5 (5.2) 0.743
Bone   2 (1.9) 5 (5.2) 0.031
Nominated lymph nodes   3 (2.8) 3 (3.1) 0.931
Combined   2 (1.9) 12 (12.5) 0.014
Values are presented as number (%).
aFisher’s exact test.Journal of The Korean Society of
Coloproctology
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respective groups. The numbers of multiple metastases and bone 
metastasis in the non-resection group were 12 (12.5%; P = 0.014) 
and 5 (5.2%; P = 0.031), respectively, and showed a statistically 
difference (P = 0.014, P = 0.031) from the values of 2 (1.9%) and 2 
(1.9%) for the resection group (Table 5).
Treatment modality
In the resection group, 35 (33.5%) right hemicolectomies were 
conducted, followed by 26 (24.8%) low anterior resections and 20 
(19.0%) anterior resections (Table 6). In the resection group, 63 
patients (60.0%) underwent post-operative chemotherapy, and in 
the non-resection group, 83 patients (86.5%) did the same. The num-
bers of patients who underwent radiotherapy were 5 (4.8%) and 
24 (25%) in respective resection and non-resection groups. Further, 
in the resection group, 42 patients (40%) did not undergo chemo-
therapy: 19 cases of refusal of treatment, 8 cases of general weak-
ness, 8 cases of being unable to monitor the patients, and 7 cases 
of post-operative complications (Table 7). Out of the total of 62 sub-
jects in the chemotherapy group, 2 patients underwent an emer-
gency colostomy during chemotherapy.
Four patients who were originally supposed to undergo a bypass 
switched to a resection: one right hemicolectomy and three low 
anterior resections. Out of the 20 bypass patients, 1 patient had to 
undergo surgery again due to an adhesive ileus. Additionally, out 
of the 14 stent insertion patients, 1 patient underwent a colostomy 
due to recurrent colonic obstruction, and another patient under-
went surgery due to peritonitis caused by a perforation.
Major post-operative complications and death rate 
After resection, 17 (16.2%) major complications, 5 cases (4.7%) of 
anastomotic leakage, 4 cases (3.8%) of bleeding, 3 cases (2.9%) of 
lung complications, 3 cases (2.9%) of ileus, 1 case (0.9%) of heart 
disease, and 1 case (0.9%) of acute renal failure, were reported. Three 
patients (2.86%) died of pulmonary edema, sepsis and multiple 
organ failure after surgery. 
 
Analysis of the prognosis factors and the survival rate 
In both the resection and the non-resection groups of advanced 
colorectal cancer patients, factors such as sex, age, ASA score, lo-
cation of the colorectal cancer lesion, existence of multiple metas-
tases and tumor differentiation were not proven to be prognostic 
factors affecting survival rates. In terms of treatment modality, 
chemotherapy alone appeared to be a significant prognosis factor 
according to the univariate analysis, but was confirmed to be sta-
tistically insignificant through the multivariate analysis. Palliative 
resection followed by chemotherapy was confirmed to be a factor 
significantly affecting survival rates according to both the univari-
ate and the multivariate analyses (relative risk [RR], 0.44; 95% 
confidence interval [CI], 0.28 to 0.69; RR, 0.47; 95% CI, 0.28 to 
0.79) (Table 8). In terms of survival rates, the group of palliative 
resection followed by chemotherapy showed a 14 months (range, 
9.6 to 18.4 months) median survival rate while the chemotherapy-
alone treatment group and the group of either stent insertion or 
bypass showed 8 months (range, 5.6 to 10.4 months) and 5 months 
median survival rates, respectively (Fig. 2).
Table 6. Types of surgery
Type
  Resection  
  (n = 105)
Non-resection  
(n = 96)
Right hemicolectomy   35 (33.3) 1 (1.0)
Left hemicolectomy   4 (3.8)
Anterior resection   20 (19.0)
Low anterior resection   26 (24.8) 3 (3.1)
Hartmann’s operation 10 (9.5)
Miles’ operation   3 (2.9)
Subtotal colectomy   6 (5.7)
Stoma formation or bypass   18 (17.1) 20 (20.8)
Values are presented as number (%).
Table 7. Patients with other combination therapies
Therapy
Resection  
(n = 105)
Non-resection  
(n = 96)
Chemotherapy 61 (58.1) 71 (74.0)
Radiation therapy 3 (2.9) 12 (12.5)
Chemotherapy and radiation 2 (1.9) 12 (12.5)
Values are presented as number (%).
Table 8. Univariate and multivariate analyses of factors associated with 
survival in incurable colorectal cancer
Factor Univariate Multivariate
Female sex 1.23 (0.91-1.67) 1.27 (0.92-1.75)
Old age (≥75 yr) 1.90 (1.28-2.82) 1.49 (0.98-2.28)
Good ASA score 0.84 (0.56-1.27) 0.95 (0.61-1.48)
Primary colon cancer 1.32 (0.98-1.77) 1.22 (0.89-1.66)
Multiple metastases 1.24 (0.93-1.66) 1.33 (0.98-1.81)
Tumor differentiation
   Well 1.00 1.00
   Moderate 0.84 (0.50-1.42) 1.02 (0.58-1.80)
   Poor 0.98 (0.52-1.83) 1.23 (0.62-2.41)
   Mucinous 0.59 (0.28-1.28) 0.80 (0.35-1.85)
Treatment modality
   Stent or bypass 1.00 1.00
   Only chemotherapy 0.62 (0.40-0.97) 0.64 (0.39-1.05)
   Only resection 0.97 (0.60-1.55) 0.93 (0.55-1.57)
   Resection + chemotherapy 0.44 (0.28-0.69) 0.47 (0.28-0.79)
Values are presented as relative risk (95% confidence interval).
ASA, American Society of Anesthesiologists.Journal of The Korean Society of
Coloproctology
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DISCUSSION
Colorectal cancer is one of the most common cancers in the US 
and Europe. In Korea, according to the 2008 statistics, colorectal 
cancer shows the third highest incidence following stomach can-
cer and thyroid cancer, and the rate is sharply increasing. About 
20% of colorectal cancer cases are considered progressive, mean-
ing radical treatment in not possible, and debates on appropriate 
treatment modalities are still going on. The palliative resection is 
one of the most frequently used methods, but not all advanced 
colorectal cancer patients are candidates for this treatment. More-
over, the post-operative death rate and the complication rate are 
known to be higher compared with those for chemotherapy, stent 
insertion or bypass; consequently, the palliative resection has been 
restrictively applied to relatively healthy patients with good condi-
tion overall and with low operative risk. This means that adopting 
a palliative resection as a standard treatment modality for advanced 
colorectal cancer patients is debatable [14]. A stent insertion or a 
bypass is used for the patients who cannot undergo a resection, 
but the use of those methods as a standard treatment modality is 
still questionable.
Different from the study results showing high survival rates after 
palliative resection treatments [3, 5, 6, 15], patients who underwent 
only resection of the primary lesion showed a 5-month median 
survival rate, which was shorter than the 8 months for the chemo-
therapy-alone treatment patients. This result implies that the con-
ventional palliative-resection-only modality cannot promise a good 
result. According to other studies, compared with chemotherapy, 
survival periods may be further extended when the palliative re-
section is restrictively used for patients having remote metastasis 
without peritoneal metastasis [3, 9, 10]. 
According to some studies, chemotherapy results in higher sur-
vival rates than palliative-resection-only does. Costi et al. [16]     
reported cases of higher survival rates with chemotherapy-alone 
treatment for patients having multiple metastases or peritoneal 
metastasis than with palliative-resection-only treatment [16]. Che-
motherapy, such as the use of 5-fluorouracil, which was developed 
in the late 1980s, and combination therapy of various agents, which 
was developed in the late 1990s, can enhance response rates of 
treatments and extend survival periods. Use of irinotecan in the 
late 1990s extended survival rates further, and introduction of   
oxaliplatin in the 2000s contributed to much better treatment re-
sults [12, 17]. In addition, with the combination therapy of beva-
cizumab and cetuximab, which were developed in the mid-2000s 
as targeted chemotherapy agents with oxaliplatin, 5-fluorouracil 
and leucovorin or irinotecan, 5-fluorouracil and leucovorin, tu-
mor response rates and survival periods were further improved 
[13, 18]. Furthermore, studies on stent insertion followed by che-
motherapy and on a palliative resection followed by chemother-
apy are in progress, and the importance of enhancing survival rate 
has been emphasized [19, 20].
At the point of diagnosing advanced colorectal cancer, 10 to 20% 
of the total cases are accompanied by partial obstruction and 8 to 
29% by complete obstruction [21]. When emergency surgery is 
conducted for these patients, a 15 to 20% death rate and about a 
50% complication rate are reported [22]. Since stent insertion was 
introduced in 1991 for treating colorectal cancer, it has been reported 
to be an effective non-surgical treatment that can relieve the symp-
toms of acute obstruction caused by the tumor [23-25]. In spite of 
the very common complications of stent insertion, such as migra-
tion of the stent, colon perforation and obstruction, the 6-month 
clinical success rate has been reported at 81% or more [24], and 
the median survival rate calculated through the present study was 
5 months. Based on these results, stent insertion may be consid-
ered to be an effective treatment modality for advanced colorectal 
cancer. In addition, the stent-related death rate has been reported 
at about 0 to 0.6% [26, 27]. Considering the high post-operative 
complication rate and death rate of colorectal cancer patients with 
obstructions, stent insertion is considered to be an effective treat-
ment modality for advanced colorectal cancer with acute obstruc-
tions not allowing a resection. However, stent-related complica-
tions reach about 30% [7, 28], and patients who undergo stent in-
sertion are usually in unfavorable conditions compared with sur-
gical resection or chemotherapy patients. Moreover, it should be 
taken into consideration that stent insertion is not a treatment that 
can enhance the survival rate. 
Another treatment for advanced colorectal cancer, such as a by-
pass including a colostomy, may also be an effective treatment mo-
dality for releasing an obstruction in colorectal cancer. Neverthe-
less, considering the risks involved in general anesthesia, as well as 
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Fig. 2. Kaplan-Meier overall survival rate curve for patients with in-
curable stage IV colorectal cancer according to their initial manage-
ment with resection and non-resection therapy. The survival rates for 
adjuvant chemotherapy, only resection therapy, only chemotherapy, 
and stent or bypass surgery were 14 months (range, 9.6 to 18.4 months), 
5 months (range, 4.1 to 5.9 months), 8 months (range, 5.6 to 10.4 
months), and 5 months (range, 3.2 to 6.8 months), respectively.Journal of The Korean Society of
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the complications and deaths related to surgery, this modality can 
be used only for releasing the obstruction, not for enhancing the 
survival rate. Like stent insertion, this is a limitation of the bypass 
[29]. In general, patients who receive non-resection treatments 
tend to have unfavorable conditions overall and to have many un-
derlying diseases compared with patients who receive resection 
treatments [15]. According to many studies, such factors as multi-
ple metastases, a tumor with poor differentiation, existence of as-
cites and age of 75 or older are related to low survival rates [3, 10, 
20]. Additionally, Kim et al. [29] reported that stage, pre-operative 
CEA values, invasions into blood vessels and nerves, and lymphatic 
metastasis affected the 5-year survival rate of perforated colorectal 
cancer patients. According to the present study, however, age, lo-
cation of the primary lesion, sex, pre-operative CEA values, multi-
ple metastases and level of differentiation of the tumor do not af-
fect survival rates.
Currently, no established guideline for the treatment of advanced 
colorectal cancer exists. As reported through many studies, it is 
evident that no single treatment modality can achieve an improve-
ment in survival rate. Kleespies et al. [10] reported statistical num-
bers in an acceptable range of complication development after sur-
gical resection of primary lesions. According to the authors’ study, 
a 16.2% (17/105) post-operative major complication rate and a 
2.86% (3/105) post-operative death rate, which are similar to those 
reported by Kleespies et al. [10], are in an acceptable range of 
complication development after surgical resection of primary         
lesions. Therefore, when patients are carefully selected, resection 
of the primary lesion may enhance the survival of the patients. By 
virtue of development of continuous and effective chemotherapy 
agents, significant improvements in survival rates may be attained. 
In addition, through the present study, a combination of palliative 
resection and post-operative chemotherapy was confirmed to fur-
ther enhance survival rates, and this result coincides with that of 
Costi et al. [16].
Even though a palliative resection of the primary lesion of ad-
vanced colorectal cancer can relieve pain, bleeding and ileus and 
can enhance survival rates compared with chemotherapy-alone 
treatment, stent insertion or a bypass, a palliative-resection-only 
treatment is not considered to be effective due to the high compli-
cation rates caused by unfavorable conditions such as old age, 
chronic diseases, recurring ileus, high surgery-related death rate, 
and anticipated limited survival period. Accordingly, selection of 
patients should be very careful before conducting a palliative re-
section and post-operative chemotherapy. For acute obstruction 
patients who cannot undergo a resection, adjuvant therapy, such 
as stent insertion and bypass, may be conducted to relieve symp-
toms and to provide a bridge for a future palliative resection to 
enhance survival.
Because this study was a retrospective one, some attention is re-
quired for interpretation of the results. Patients, guardians and doc-
tors were involved in selecting the treatment method, in which 
may increase the risk of error. Different chemotherapy agents were 
administered to patients, which also increase the in risk of errors. 
That the best treatment modality can only be decided based on a 
random prospective study is common knowledge.
In case of advanced colorectal cancer, good treatment results can 
hardly be obtained through a palliative-resection-only treatment 
compared with a non-resection treatment. Accordingly, upon con-
sideration of the general condition of advanced colorectal cancer 
patients having accompanying symptoms, a combination of a pal-
liative resection of the primary lesion and post-operative chemo-
therapy may enhance survival rates.
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